Tenofovir treatment augments anti-viral immunity against drug-resistant SIV challenge in chronically infected rhesus macaques

Table 1 Immunization history and baseline characteristics of rhesus macaques prior to tenofovir treatment

			SIVmac239Δnef proviral load		Lymphocyte counts (cells/mm³)^d		SIVmac239Δnef plasma viral load^e
Macaque	SIV infection^a	Protection against SIVmac251 challenge^b	DNA copies/10⁶ genomic equivalents^c	Tenofovir	CD4⁺ T cells	CD8⁺ T cells	(RNA copies/ml plasma
P512	-	ND	ND	+	1039	705	< 50
P679	-	ND	ND	+	793	609	< 50
P804	-	ND	ND	+	989	847	< 50
P806	-	ND	ND	+	512	371	< 50
1494	SIVmac239Δnef	+	29 ± 23	-	558 ± 21	520 ± 75	1.5 × 10³
1512	SIVmac239Δnef	+	14 ± 9	-	868 ± 207	864 ± 269	5.5 × 10²
1488	SIVmac239Δnef	+	66 ± 41	+	725 ± 82	753 ± 208	< 50
1498	SIVmac239Δnef	+	12 ± 10	+	669 ± 61	1471 ± 343	3.5 × 10³
1514	SIVmac239Δnef	+	291 ± 123	+	703 ± 180	963 ± 342	< 50

^a Macaques were infected with SIVmac239Δnef approximately 3 years prior to initiation of this study [16]
^b Challenge with SIVmac251 was carried out from 10 and 25 weeks after immunization with SIVmac239Δnef [16]
^c Mean ± standard deviation of 5–7 time points within 2.5 years before administration of tenofovir
^d Mean ± standard deviation of days -14, -6 and 0 before administration of tenofovir
^e Day 0 before administration of tenofovir

ISSN: 1742-4690